RightEye

RightEye

FDA-cleared eye-tracking system for vision health

Overview

RightEye develops an FDA-cleared eye-tracking platform that records and analyzes eye movements to assess vision and brain health. Patients complete five-minute, game-like tests on a screen while the system collects data and generates a report that compares results to normative data. The platform is used by optometrists, hospitals, and professional sports teams for concussion screening, functional vision assessment, and early detection of conditions like Parkinson's disease. Its goal is to replace subjective observations with objective, quantitative measurements to improve diagnosis, monitoring, and outcomes.

About RightEye

Simplify's Rating
Why RightEye is rated
C+
Rated B on Competitive Edge
Rated C on Growth Potential
Rated C on Differentiation

Industries

Data & Analytics

Enterprise Software

Healthcare

Company Size

11-50

Company Stage

Debt Financing

Total Funding

$13.4M

Headquarters

Bethesda, Maryland

Founded

2012

Get referred to RightEye

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • The 2026 Software Engineer posting signals active product development, not shutdown.
  • RightEye's website now promotes automated sensorimotor exams, supporting practice revenue adoption.
  • Federal and Canadian reseller access through ADS and RAMPART expands institutional sales reach.

What critics are saying

  • RightEye listed only 17 employees in 2025, limiting commercialization and clinical validation capacity.
  • Revenue depends on resellers like Bernell and ADS, creating channel concentration risk.
  • RightEye's patent application remains ungranted; competitors can copy faster than approvals.

What makes RightEye unique

  • RightEye combines FDA-cleared eye tracking with insurer-reimbursable sensorimotor exams.
  • Its 2025 patent filing extends machine-learning eye tracking into physiological-state assessment.
  • MIT collaboration on Lyme biomarker research broadens RightEye beyond routine vision screening.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$13.3M

Above

Industry Average

Funded Over

6 Rounds

Debt funding comparison data is currently unavailable. We're working to provide this information soon!
Debt Funding Comparison
Coming Soon

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-5%
InDepth Vision
Nov 21st, 2022
What Makes InDepth Vision Stand Out

Indepthvision recently purchased the Right Eye, an innovative eye-tracking technology that allows Indepthvision to assess eye movements and track reaction times accurately.

RightEye
Apr 25th, 2022
RightEye LLC partners with Massachusetts Institute of Technology

RightEye, the world’s leading eye-tracking biomarker company, has signed a research collaboration agreement with the Massachusetts Institute of Technology (MIT) to study an oculomotor “signature” for Lyme disease.

Ophthalmology Times
Aug 23rd, 2021
RightEye launches automated, quantitative sensorimotor exam system

RightEye LLC, an eye-tracking technology company, has launched an automated, quantitative sensorimotor exam system.

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for RightEye right now.

Find jobs on Simplify and start your career today

We update RightEye's jobs every few hours, so check again soon! Browse all jobs →